Call for Grant Applications (CGA)

Clinical Advances in Merkel Cell Carcinoma (MCC)
Supporting Local and Regional Activities for Community Oncologists

Pfizer - Independent Grants for Learning & Change (IGLC) and EMD Serono Global Medical Education (GME) are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology.

MCC is a rare and aggressive disease in which cancer cells form in the top layer of the skin, close to nerve endings. MCC, which is also known as neuroendocrine carcinoma of the skin or trabecular cancer, often starts in those areas of skin that are most often exposed to the sun, including the head and neck, arms, legs, and trunk. Risk factors for MCC include sun exposure and having a weak immune system. Solid organ transplant recipients, people with HIV/AIDS and people with other cancers, such as chronic lymphocytic leukemia, are at higher risk. Caucasian males over age 50 are also at increased risk. MCC tends to metastasize at an early stage, spreading initially to nearby lymph nodes, and then potentially to more distant areas in the body, including other lymph nodes or areas of skin, lungs, brain, bones or other organs. Current treatment options for MCC include surgery, radiation and chemotherapy. Treatment for metastatic or Stage IV MCC is generally palliative. A variety of investigative immunotherapy options for MCC are being explored worldwide.

<table>
<thead>
<tr>
<th>Date CGA Issued:</th>
<th>February 28, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area:</td>
<td>Merkel Cell Carcinoma (MCC)</td>
</tr>
<tr>
<td>Geographic Scope:</td>
<td>☑ United States Only</td>
</tr>
</tbody>
</table>
| Specific Area of Interest for this CGA: | Pfizer IGLC and EMD Serono GME are collaborating to support independent education for community oncologists that focuses on increasing the awareness and detection of MCC, managing immune-mediated adverse reactions, and advancing the understanding of emerging treatment options for patients with MCC, including, without limitation, immunotherapy. This CGA is requesting grant applications for proposals that will help community oncologists stay abreast of emerging data in MCC and emerging treatment options. Proposals may include activities such as:

- On-agenda sessions at established conferences
- Mini symposia alongside established conferences
- Regional live meetings, workshops, grand rounds, tumor board presentations, etc.
- Online tools, printed handouts, and other enduring materials

The content and/or the format of the activities and the related materials must be designed in such a way that they addresses the evolving educational needs of health care professionals and, if appropriate, tools/aids that can help health care professionals diagnose MCC, manage immune-mediated adverse reactions, and better communicate with and manage their patients.

Proposals may include scientific course content on a wide range of topics from understanding the science of mechanisms of action of emerging treatment options to more practical information for clinical application using MCC patient-case-based discussions. |
| Applicant Eligibility Criteria: | The following organizations may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

Important note for this CGA: US organizations must be accredited providers of continuing medical education and cannot be physician-owned clinics, managed care organization or pharmacy benefit managers.

All activities must be “independent” which means free from the influence or control of any commercial entity. Activities must also be accredited/certified for CME/CE credit.

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions and organizations are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role. |
| **Expected Approximate Monetary Range of Grant Applications:** | Proposals requesting up to a maximum of $75,000 USD will be considered. Smaller educational grant requests in the $5K to $25K range are strongly encouraged.

The total available budget related to this CGA is $200,000 USD.

The grant amount Pfizer and EMD Serono will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification. |
|---|---|
| **Key Dates:** | CGA release date: February 28, 2017

Grant application due date: April 5, 2017
Please note the deadline is midnight US Eastern Time (New York, GMT - 5).

Anticipated Grant Award Notification Date: May 17, 2017

Grants distributed following execution of fully signed Letter of Agreement

Period of Performance: June 2017 to June 2018 (priority will be given to programs that take place in 2017) |
| **How to Submit an Application:** | Please go to the website at [www.cybergrants.com/pfizer/knowledge](http://www.cybergrants.com/pfizer/knowledge) and click on the button “Go to the Grant System.” Registered users should select the appropriate link under Track 2 – Knowledge Gap

If this is your first time visiting this site you will be prompted to take the Eligibility Quiz to determine the type of support you are seeking. Please ensure you identify yourself as a first-time user.

Select the following Educational Area: **CGA- MCC**

Requirements for submission:
Complete all required sections of the online application and upload the completed CGA template (see Appendix).

If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page |
| **Questions:** | If you have questions regarding this CGA, please direct them in writing to Derek Warnick at (derek.warnick@pfizer.com), with the subject line “MCC CGA” |
| **Mechanism by which Applicants will be Notified:** | All applicants will be notified via email by the dates noted above.

Applicants may be asked for additional clarification or to make a summary presentation during the review period. |
IV. Terms and Conditions

1. This CGA does not commit Pfizer or EMD Serono to award a grant or a grant of any particular size if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.

2. Pfizer and EMD Serono reserve the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety, if it determines it is in the best interest of Pfizer and its partners to do so.

3. For compliance reasons and in fairness to all applicants, all communications about the CGA must come exclusively to Pfizer IGLC or to EMD Serono GME. Failure to comply will disqualify applicants.

4. Consistent with its commitment to openness and transparency, Pfizer reports education grants provided to medical, scientific, and patient organizations in the United States. Pfizer reserves the right to announce the details of successful grant application(s) by whatever means insures transparency, such as on the Pfizer website, in presentations, and/or in other public media.

5. Pfizer and EMD Serono reserve the right to share with organizations that may be interested in contacting you for further information (e.g., possible collaborations) the title of your proposed project and the name, address, telephone number, and e-mail address of the applicant from the requesting organization.

6. To comply with 42 U.S.C. § 1320a-7h and 42 C.F.R. §§ 403.900-.914 (the Sunshine Act), Provider (sponsor) must provide to Pfizer specific information for the U.S.-licensed physicians and U.S. teaching hospitals (“Covered Recipients,” as defined by applicable law) to whom Provider (sponsor) furnished payments or other transfers of value from the original independent grant awarded by Pfizer. Those payments or transfers-of-value include compensation, reimbursement for expenses, and meals provided to faculty (planners, speakers, investigators, project leads, etc.) and “items of value” (items that possess a discernable value on the open market, such as textbooks) provided to faculty and participants, if those faculty and/or participants meet the definition of Covered Recipient. Provider (sponsor) must submit the required information during the reconciliation process or earlier, upon Pfizer’s request, so Pfizer can meet Sunshine Act reporting commitments. Be advised that Pfizer will not make any payments to any individuals; grant funding shall be paid directly to Provider (sponsor).

Frequently Asked Questions related to IGLC’s Sunshine Act Reporting Requirements are available on our website (http://www.pfizer.com/files/IGLCsunshineFAQ_updatedJan2016.pdf).

7. No portion of a Pfizer or EMD Serono independent grant may be used for food and/or beverages for learners and/or participants in any capacity. Provider (sponsor) will be required to certify during the reconciliation process and/or the periodic collection of Sunshine reporting that funds were not used for food and/or beverages for learners and/or participants.

8. In the performance of all activities related to an independent grant, the Provider (sponsor) and all participants must comply with all applicable Global Trade Control Laws. “Global Trade Control Laws” include, but are not limited to, U.S. Export Administration Regulations; the International Traffic in Arms Regulations; EU export controls on dual-use goods and technology; Financial Sanctions Laws and Restrictive Measures imposed within the framework of the CFSP -
Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

A. Title
B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
C. Goal: Briefly state the overall goal of the project.
D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.
H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
K. Timeline
L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
M. References (outside the 15-page limit)
   • There is no designated format for references
N. Budget (See template available in application)
   • While estimating your budget please keep the following items in mind:
     • Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
     • Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
     • A separate Excel file should be uploaded. This does not count toward the page limit.
• An example of the budget template can be found here: http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls
• At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. There is a 15-page limit exclusive of references. If extensive, references may be included on 1-2 additional pages.